Success Stories

Tuesday, 28 April 2020 14:32

ACTO Technologies Inc

SOFII funding was used for working capital to rapidly gain market share by expanding their sales and customer success teams and increasing content marketing initiatives.

 


ACTO Technologies Inc

LOCATION Toronto, Ontario
FUNDING RECEIVED $500,000
JOBS MAINTAINED 24 FTE
FORECASTED JOBS CREATED 30 FTE (New jobs created from SOFII funding)
WEBSITE www.actoapp.com

BUSINESS DESCRIPTION

ACTO Technologies has developed a SaaS based sales, marketing, and training platform designed specifically for organizations within the life sciences sector. ACTO’s Commercialization Cloud is a full-suite platform providing sales, training, and marketing systems when drugs and devices enter the stream of commerce. ACTO is currently the only complete solution (other companies only offer point solutions) uniquely designed for the life sciences sector to help increase sales and brand awareness while reducing compliance risks. They help pharmaceutical, medical device and dental companies increase rep effectiveness, message consistency and build a culture of continuous learning while helping them stay compliant.

SOFII PROJECT SUMMARY

SOFII funding was used for working capital to rapidly gain market share by expanding their sales and customer success teams and increasing content marketing initiatives.

TESTIMONIAL

"ACTO is on a mission to help life sciences companies promote on clinical value. As a Toronto start-up thriving in the vast technology ecosystem, we identified the main factor limiting our growth: human capital. Since working with SOFII we have been able to hire 12 individuals spanning across all 4 of our functional units. To aid in achieving our revenue targets, we brought on two tenured sales professionals to add to our commercial team. Building the foundation of our brand new marketing initiatives has been accelerated with two key hires rounding off their team. With the introduction of our new Product Manager, we have been able to establish processes to increase efficiency among our developers and technical literacy within our commercial team.

In short, looking back 2019 we can attribute a strong finish to the SOFII program and have since successfully solidified our Series A investment round. We look forward to continued success hand in hand with SOFII as we continue the momentum into 2020 and give incredible opportunities to those looking to make an impact on the life science industry with us here in Ontario."